First look at Verve study data offer base editing ‘proof of principle’

Sekar Kathiresan started Verve Therapeutics five years ago in pursuit of a powerful idea: develop a one-time gene editing treatment to permanently lower cholesterol and, with it, heart disease risk. Early study results revealed Sunday show his ambitious plan has a chance at working.